Engineered viral vector reduces induction of inflammatory and immune responses
AssigneePresident and Fellows of Harvard College
InventorsYing Kai Chan, George M. Church
Life of this patent
Estimating the term…
Abstract
Modified viral genomes are able to reduce induction of inflammatory and immune anti-viral responses. This manifests itself in reduced NF-kB activity, increased viral transduction rates, and increased expression of transgenes. Viral genomes are modified by incorporating one or more oligonucleotide sequences which are able to bind to TLR9 but not induce activation of it. The oligonucleotide sequences may be synthetic, bacterial, human, or from any other source.
Claims22
A recombinant viral genome covalently linked to an inhibitory nucleic acid sequence that binds to TLR9 but does not trigger TLR9 activation, wherein the viral genome is self-complementary, wherein the inhibitory nucleic acid sequence comprises the nucleotide sequence of SEQ ID NO:
- 1.
A recombinant viral genome covalently linked to an inhibitory nucleic acid sequence that binds to TLR9 but does not trigger TLR9 activation, wherein the inhibitory nucleic acid sequence is at least 95% identical to the nucleotide sequence of SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.